FCM
CNST

Farallon Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Farallon Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000,000
Closed -$23.4M – 385
2021
Q1 		$23.4M Buy
1,000,000
+250,000
+33% +$7.57M 0.12% 99
2020
Q4 		$21.6M Buy
+750,000
New +$18.9M 0.13% 86
2020
Q3 		– Sell
-350,000
Closed -$10.5M – 141
2020
Q2 		$10.5M Buy
+350,000
New +$12.6M 0.08% 101

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Farallon Capital Management's CNST Position: Q2 2021 in Review

Farallon Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 1,000,000 shares — an estimated $23.4M sold.

Farallon Capital Management first reported a position in CNST in Q2 2020 and held it in 3 quarters. The position peaked at $23.4M in Q1 2021. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Farallon Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Farallon Capital Management sold 1,000,000 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $23.4M.
  • Farallon Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
  • Farallon Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $23.4M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.